Literature DB >> 27792061

Fibrin Ring Granulomas in Checkpoint Inhibitor-induced Hepatitis.

Jamie Everett1, Amitabh Srivastava, Joseph Misdraji.   

Abstract

Fibrin ring granulomas are an uncommon finding in liver biopsies although they have been described in liver injury secondary to several infectious and noninfectious entities, most notably Q fever. Immune checkpoint inhibitors are recent advances in cancer therapy, and stimulate the immune system to cause antitumoral effects but may also lead to adverse immune events such as hepatitis and colitis. We report 2 patients on combination ipilimumab/nivolumab who developed hepatitis and had fibrin ring granulomas in their liver biopsies.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27792061     DOI: 10.1097/PAS.0000000000000759

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  20 in total

Review 1.  [The pathology of adverse events with immune checkpoint inhibitors].

Authors:  V H Koelzer; K Glatz; L Bubendorf; A Weber; A Gaspert; G Cathomas; A Lugli; A Zippelius; W Kempf; K D Mertz
Journal:  Pathologe       Date:  2017-05       Impact factor: 1.011

2.  Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.

Authors:  Michael Li; Jordan S Sack; Osama E Rahma; F Stephen Hodi; Stephen D Zucker; Shilpa Grover
Journal:  Cancer       Date:  2020-09-05       Impact factor: 6.860

Review 3.  Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.

Authors:  Petros Fessas; Lucia A Possamai; James Clark; Ella Daniels; Cathrin Gudd; Benjamin H Mullish; James L Alexander; David J Pinato
Journal:  Immunology       Date:  2019-11-19       Impact factor: 7.397

4.  Hepatobiliary and Pancreatic Adverse Events.

Authors:  Hao Chi Zhang; Lan Sun Wang; Ethan Miller
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Morphology of tumor and nontumor tissue in liver resection specimens for hepatocellular carcinoma following nivolumab therapy.

Authors:  Camila C Simoes; Swan N Thung; Maria Isabel Fiel; Max W Sung; Myron E Schwartz; Stephen C Ward
Journal:  Mod Pathol       Date:  2020-09-28       Impact factor: 7.842

Review 6.  Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives.

Authors:  Michael Dougan
Journal:  Curr Gastroenterol Rep       Date:  2020-03-17

Review 7.  Liver Histology: Diagnostic and Prognostic Features.

Authors:  Billel Gasmi; David E Kleiner
Journal:  Clin Liver Dis       Date:  2019-10-31       Impact factor: 6.126

8.  Immunotherapy-related hepatitis: real-world experience from a tertiary centre.

Authors:  Vincent Cheung; Tarun Gupta; Miranda Payne; Mark R Middleton; Jane D Collier; Alison Simmons; Paul Klenerman; Oliver Brain; Jeremy F Cobbold
Journal:  Frontline Gastroenterol       Date:  2019-03-22

9.  Efficacy of artificial liver support system in severe immune-associated hepatitis caused by camrelizumab: A case report and review of the literature.

Authors:  You-Wen Tan; Li Chen; Xing-Bei Zhou
Journal:  World J Clin Cases       Date:  2021-06-16       Impact factor: 1.337

Review 10.  Liver damage related to immune checkpoint inhibitors.

Authors:  Naoshi Nishida; Masatoshi Kudo
Journal:  Hepatol Int       Date:  2019-01-03       Impact factor: 9.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.